Semax vs selank: how these two Russian peptides differ

Last updated 2026-07-26

What is the actual difference between semax and selank?

Semax is a synthetic heptapeptide developed from a fragment of ACTH (adrenocorticotropic hormone), first studied in the Soviet Union in the 1980s at the Institute of Molecular Genetics and later developed with the Institute of Normal Physiology in Moscow. Selank is a synthetic peptide built from tuftsin, a naturally occurring immunomodulatory peptide, developed by the same Russian research groups roughly a decade later. They share intellectual lineage but not structure or primary use case. In plain terms: semax was designed around cognitive and neuroprotective outcomes. Russian trials looked at stroke recovery, attention deficit issues, and general cognitive decline. Selank was designed as an anxiolytic, tested mostly for generalized anxiety disorder and stress-related conditions, with cognitive benefits treated as secondary. People conflate the two because they're often sold by the same suppliers, dosed similarly (intranasal sprays, injectable vials), and both marketed loosely as 'Russian nootropic peptides.' But if you're choosing based on a specific goal, anxiety versus focus, they're not interchangeable in the way two SSRIs might be. Both are registered as medications in Russia under the brand names Semax (0.1% nasal solution) and Selank, and both are manufacturers through Russian pharmaceutical firms including Peptogen and Innovative Pharmacological Developments. Neither has ever gone through FDA review as a prescription drug in the United States.

Semax vs selank: quick comparison table

Does semax or selank work better for anxiety?

Selank is the one built and tested for anxiety specifically. Russian trials, including a placebo-controlled study published in the journal Neuroscience and Behavioral Physiology, evaluated selank in patients with generalized anxiety disorder and adjustment disorders with anxiety, reporting reductions in anxiety scores comparable to some benzodiazepine and antidepressant comparators over short treatment windows ^[3]. Semax has some anxiolytic-adjacent findings in animal models (reduced anxiety-like behavior in rodent studies) but its human trial base is centered on cognitive and neurological recovery, not anxiety disorders specifically ^[4]. If your primary complaint is anxiety, selank is the peptide with a use case actually built for it. Semax's mood effects, where reported, tend to show up as a side benefit of cognitive studies, not as a primary endpoint. One caveat that applies to both: essentially all of this evidence is Russian-language, published in Russian journals or Russian-affiliated international journals, using methodologies that don't match the randomized, multi-site, pre-registered trial standards Western regulators expect. Sample sizes in the selank anxiety trials are typically in the dozens to low hundreds, not the thousands you'd see in an FDA New Drug Application. That doesn't make the data worthless. It makes it preliminary by US standards.

Is semax or selank better for focus and cognition?

Semax has the deeper cognitive literature. It was studied for optic nerve atrophy, ischemic stroke recovery, and attention deficit disorder in children, with reported improvements in attention and memory tasks in several small Russian trials dating back to the 1990s and 2000s ^{[4] [5]}. Its proposed mechanism involves upregulating BDNF (brain-derived neurotrophic factor) and modulating the MEK/ERK signaling pathway, both plausible mechanisms for cognitive effects, though the human data supporting this in a rigorous, blinded, adequately powered way is thin outside Russia. Selank's cognitive data is secondary. Some Russian studies on generalized anxiety patients note improved attention or reduced cognitive fatigue as anxiety symptoms improve, which is a common finding with any effective anxiolytic (less anxiety often means better working memory) rather than evidence of a direct nootropic effect. If your goal is pure focus or studying performance, semax has the more relevant, if still limited, literature. If your anxiety is what's tanking your focus, selank might address the root cause more directly. Neither has a Western double-blind trial that would satisfy a skeptical clinician or a peer reviewer at a major US journal.

Can you take semax and selank together?

Yes, and it's a common combination among people who use both. Because they act through different proposed mechanisms (semax more on the BDNF/dopaminergic side, selank more on GABAergic and enkephalin pathways) there's a plausible rationale for using semax during the day for focus and selank for anxiety or before stressful demands. No published clinical trial has tested the combination specifically, in Russia or anywhere else, so any claimed combined benefit is anecdotal, not evidenced. If you're considering stacking, read Selank stack with other peptides for a fuller rundown of what's actually been reported versus what's forum speculation. The practical concern isn't drug interaction risk (peptides at these doses haven't shown dangerous interactions in the literature) but sourcing risk: doubling the number of unregulated products you're injecting or spraying doubles your exposure to contamination, mislabeled concentration, or degraded product if either is stored or shipped wrong.

How do the side effect profiles compare?

Both peptides report mild, similar side effect profiles in the Russian literature: nasal irritation with intranasal dosing, mild headache, occasional drowsiness or, less commonly, agitation. Neither has a US FDA-monitored adverse event database, so the side effect data comes entirely from Russian trial reports and post-marketing surveillance within Russia, not from the kind of large-scale pharmacovigilance system the US uses for approved drugs. Selank's tuftsin-derived structure raises a theoretical question about immune modulation, since tuftsin itself affects immune cell activity, though no Russian trial has reported clinically significant immune side effects at studied doses. Semax's ACTH-derived structure raises a theoretical question about interaction with the hypothalamic-pituitary-adrenal axis, though again, no strong signal for this in the published trials. Neither peptide has been studied for long-term daily use beyond a few months in any published trial. If you're using either for more than the trial durations (typically 10 to 24 days in the Russian studies), you're outside the evidence base entirely, for both.

Why is most of the research only in Russian?

Because both peptides were developed, tested, and commercialized entirely within Russian pharmaceutical and academic institutions, with essentially no Western pharmaceutical company ever picking up either molecule for international trials. Semax and selank are both registered medications in Russia, sold under prescription for their approved indications, and studied primarily by Russian research groups publishing in Russian-language journals or in journals like Neuroscience and Behavioral Physiology (an English-translation journal that carries a lot of this literature) ^[3]. No Phase 3 trial meeting FDA or EMA standards exists for either peptide. That's not a minor footnote, it's the central fact anyone researching these peptides needs to sit with. Russian drug registration involves real clinical testing and real regulatory review, but the bar, the trial size norms, and the transparency standards differ substantially from FDA processes. A Russian-approved drug is not the equivalent of an FDA-approved drug, and treating Russian registration as if it were interchangeable with US approval is a common and important error. At the same time, dismissing the literature outright isn't accurate either. These are real trials, published with real methodology sections, run by real institutions (the Institute of Molecular Genetics of the Russian Academy of Sciences did foundational work on both peptides), just not replicated or reviewed by the mechanisms Western researchers and regulators rely on ^[5]. The honest position is: interesting, plausible, understudied by international standards, not verified independently.

What do the mechanisms of action actually claim?

Semax's proposed mechanism centers on upregulating brain-derived neurotrophic factor (BDNF) expression and activating the MEK/ERK signaling cascade, pathways linked to neuronal survival and synaptic plasticity in animal studies ^[4]. It's also proposed to modulate dopaminergic and serotonergic activity, which would explain reported mood and attention effects. Selank's proposed mechanism centers on modulating GABAergic transmission and inhibiting the enzyme that degrades enkephalins (endogenous opioid-like peptides tied to mood regulation), alongside effects on the balance of pro-inflammatory and anti-inflammatory cytokines, an angle tied to its tuftsin-derived immune heritage ^[3] . This is proposed as the basis for its anxiolytic effect without the sedation or dependence profile associated with benzodiazepines. Both mechanism stories are plausible and consistent with animal pharmacology data. Neither has been confirmed with the kind of receptor-binding, PET-imaging, or large human pharmacokinetic studies that would move them from 'proposed mechanism' to 'established mechanism' in a Western pharmacology textbook.

How does selank compare to prescription anxiety medications?

Short answer: on paper, Russian trials suggest selank performs comparably to some benzodiazepines and antidepressants on anxiety rating scales over short trial periods, without the sedation or dependence liability of benzodiazepines ^[3]. That's a meaningful claim if true, but it comes from a research base that hasn't been replicated outside Russia, uses shorter trial durations than most SSRI trials, and hasn't gone through FDA-style meta-analysis across multiple independent sites. For a much fuller comparison against SSRIs specifically, including how the trial designs differ and what an honest risk-benefit read looks like, see Selank vs SSRI. The short version: SSRIs have decades of large, multi-site, FDA-reviewed trials behind them, plus known long-term safety data. Selank has neither, and anyone choosing between the two should treat that gap as the deciding factor, not a footnote.

How are semax and selank typically dosed and administered?

Semax is most commonly used as a 0.1% intranasal solution, with Russian clinical dosing in trials ranging roughly from 250 micrograms to 1 milligram per day, split across one or two nasal administrations ^{[4] [5]}. Selank is typically used as a nasal spray at concentrations around 0.15%, with trial dosing generally in the range of 200 to 900 micrograms per day, again usually split across two administrations ^[3]. Both are also sold as injectable vials for research use, dosed in similar microgram ranges subcutaneously, though the injectable route has less direct trial support than the intranasal route used in most published Russian studies. If you're deciding on storage or administration logistics for either, the practical concerns (temperature sensitivity, shelf life once reconstituted, injection site rotation) are covered in more depth at Selank storage and shelf life, does Selank need to be refrigerated, and Selank injection sites. Neither peptide has an FDA-reviewed dosing label, so any dose range cited here reflects what Russian trials used, not an official prescribing guideline recognized in the US.

Which one should you actually pick: semax or selank?

If anxiety, stress reactivity, or irritability is your main problem, selank has the more directly relevant Russian trial base and the clearer proposed mechanism for that specific complaint ^[3]. If cognitive performance, attention, or recovery from a neurological insult is your main problem, semax has the deeper (though still Russian-only) trial history ^{[4] [5]}. If you genuinely can't tell which is driving the other (anxiety wrecking your focus, or foggy cognition making you anxious about performance), that ambiguity itself is useful information, and it's a reasonable case for why people stack the two rather than picking one. Whatever you choose, treat sourcing as the part of this decision you actually control. The clinical questions (does it work, how well, for whom) are stuck at 'promising but not independently verified' until someone runs a real Western trial. The sourcing question (is this vial actually what the label says, at the stated purity) is answerable right now, and it's where most of the real risk lives. Selank Co works with a provider-reviewed pharmacy partner and lists certificate of analysis documentation for exactly this reason; if you want to see what a real COA should include before you buy from anyone, Selank certificate of analysis explained walks through it line by line.

Frequently asked questions

Is semax stronger than selank?

They're not directly comparable on a single strength scale because they target different things. Semax's trial base is stronger for cognitive and neurological outcomes; selank's trial base is stronger for anxiety. 'Stronger' only makes sense once you specify which effect you're asking about.

Can selank cause anxiety instead of reducing it?

Uncommonly, some users report initial jitteriness or agitation, particularly at higher doses or early in use, though Russian trials generally report anxiolytic effects, not anxiogenic ones. If you notice increased anxiety, that's a signal to lower the dose or stop, not push through.

Does selank help with depression?

Some Russian research and post-marketing reports mention mood improvement in patients with mixed anxiety-depressive symptoms, but selank was designed and tested primarily as an anxiolytic, not an antidepressant, and depression-specific trials are limited compared to the anxiety trial base ^[5].

Is semax approved by the FDA?

No. Semax is registered as a prescription medication in Russia but has never gone through FDA review or approval in the United States. It's sold in the US market as a research chemical, not as an approved drug for any condition.

Is selank approved by the FDA?

No. Selank is registered in Russia (since roughly 2009) as a prescription anxiolytic nasal spray, but it has no FDA approval, no NDA on file, and no Western regulatory recognition as a medication.

Can you take semax for anxiety instead of selank?

You can, and some users do, but semax's trial base is centered on cognition and neuroprotection, not anxiety disorders. If anxiety is your primary target, selank has the more directly relevant Russian clinical literature behind it.

Do semax and selank show up on a drug test?

Neither is a standard drug test target in the US, since both are peptides outside typical workplace or federal testing panels (which focus on substances like THC, opioids, and amphetamines). There's no published data confirming they're undetectable in all testing contexts, so caution is reasonable in safety-sensitive jobs.

What's the difference between semax and N-acetyl semax?

N-acetyl semax (sometimes sold as Semax NA) is a modified version with an acetyl group added, marketed as having a longer half-life than standard semax. It has even less independent trial support than standard semax, most of the claims come from manufacturer literature and anecdotal reports, not peer-reviewed trials.

How long do semax and selank take to work?

Russian trial reports for selank describe anxiolytic effects emerging within the first few days of a 10 to 14 day course ^[5]. Semax's cognitive trials generally used similar short courses, with effects assessed at the end of treatment rather than within hours of a single dose.

Are semax and selank legal to buy in the United States?

They're sold in the US as research chemicals, not as approved drugs, meaning they exist in a regulatory gray zone: not FDA-approved for human use, not scheduled as controlled substances, generally sold labeled 'not for human consumption.' Buyers should understand this is a real legal ambiguity, not a technicality.

Which peptide has more human trial data, semax or selank?

Semax has the longer trial history, dating back to the late 1980s and early 1990s with dozens of published Russian studies across stroke, ADHD, and cognitive impairment. Selank's trial base is newer (starting in the 2000s) and more narrowly focused on anxiety disorders ^[5][6][7].

Can semax and selank be used long term?

Neither has published trials extending much past a few months of use. Most Russian clinical trials for both peptides run 10 to 24 days per course, sometimes repeated. There's no solid data on daily use across years, so long-term safety is genuinely unknown for both.

Sources

1. National Center for Biotechnology Information, PubChem Compound Summary for Semax: Semax structure and classification as an ACTH(4-10) analog
2. National Center for Biotechnology Information, PubChem Compound Summary for Selank: Selank structure and classification as a tuftsin analog
3. National Center for Biotechnology Information, PubMed review of Semax neuroprotective and cognitive effects: Semax mechanism involving BDNF upregulation and cognitive/neuroprotective effects
4. National Center for Biotechnology Information, PubMed study on Semax in ischemic stroke: Semax studied in Russian trials for ischemic stroke recovery
5. National Center for Biotechnology Information, PubMed study on Selank immunomodulatory and anxiolytic mechanisms: Selank mechanism involving enkephalin degradation inhibition and cytokine modulation